Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
Identifieur interne : 001967 ( Ncbi/Merge ); précédent : 001966; suivant : 001968Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
Auteurs : Fabrice André [France] ; Ruth O'Regan [États-Unis] ; Mustafa Ozguroglu [Turquie] ; Masakazu Toi [Japon] ; Binghe Xu [République populaire de Chine] ; Guy Jerusalem [Belgique] ; Norikazu Masuda [Japon] ; Sharon Wilks [États-Unis] ; Francis Arena [États-Unis] ; Claudine Isaacs [États-Unis] ; Yoon-Sim Yap [Singapour] ; Zsuzsanna Papai [Hongrie] ; Istvan Lang [Hongrie] ; Anne Armstrong [Royaume-Uni] ; Guillermo Lerzo [Argentine] ; Michelle White [Australie] ; Kunwei Shen [République populaire de Chine] ; Jennifer Litton [États-Unis] ; David Chen [États-Unis] ; Yufen Zhang [États-Unis] ; Shyanne Ali [États-Unis] ; Tetiana Taran [États-Unis] ; Luca Gianni [Italie]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (administration et posologie), Estimation de Kaplan-Meier, Femelle, Gènes erbB-2, Humains, Modèles de hasards proportionnels, Méthode en double aveugle, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résistance aux médicaments antinéoplasiques (), Résultat thérapeutique, Sirolimus (analogues et dérivés), Sirolimus (usage thérapeutique), Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Trastuzumab, Tumeurs du sein (génétique), Tumeurs du sein (mortalité), Tumeurs du sein (traitement médicamenteux), Évérolimus.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés.
- analogues et dérivés : Sirolimus.
- génétique : Tumeurs du sein.
- mortalité : Tumeurs du sein.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique, Sirolimus.
- Adulte, Adulte d'âge moyen, Estimation de Kaplan-Meier, Femelle, Gènes erbB-2, Humains, Modèles de hasards proportionnels, Méthode en double aveugle, Résistance aux médicaments antinéoplasiques, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Trastuzumab, Évérolimus.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Breast Neoplasms (drug therapy), Breast Neoplasms (genetics), Breast Neoplasms (mortality), Disease-Free Survival, Double-Blind Method, Drug Resistance, Neoplasm (drug effects), Everolimus, Female, Genes, erbB-2, Humans, Kaplan-Meier Estimate, Middle Aged, Proportional Hazards Models, Sirolimus (analogs & derivatives), Sirolimus (therapeutic use), Trastuzumab, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized.
- chemical , analogs & derivatives : Sirolimus.
- drug effects : Drug Resistance, Neoplasm.
- drug therapy : Breast Neoplasms.
- genetics : Breast Neoplasms.
- mortality : Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Sirolimus.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Double-Blind Method, Everolimus, Female, Genes, erbB-2, Humans, Kaplan-Meier Estimate, Middle Aged, Proportional Hazards Models, Trastuzumab, Treatment Outcome.
Abstract
Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.
DOI: 10.1016/S1470-2045(14)70138-X
PubMed: 24742739
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003810
- to stream PubMed, to step Curation: 003696
- to stream PubMed, to step Checkpoint: 003696
Links to Exploration step
pubmed:24742739Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.</title><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, INSERM Unit U981, Université Paris Sud, Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, INSERM Unit U981, Université Paris Sud, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="O Regan, Ruth" sort="O Regan, Ruth" uniqKey="O Regan R" first="Ruth" last="O'Regan">Ruth O'Regan</name><affiliation wicri:level="2"><nlm:affiliation>Winship Cancer Institute of Emory University, Atlanta, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Winship Cancer Institute of Emory University, Atlanta, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Ozguroglu, Mustafa" sort="Ozguroglu, Mustafa" uniqKey="Ozguroglu M" first="Mustafa" last="Ozguroglu">Mustafa Ozguroglu</name><affiliation wicri:level="1"><nlm:affiliation>Cerrahpasa Medical Faculty, Department of Medicine, Division of Medical Oncology, Istanbul University, Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Cerrahpasa Medical Faculty, Department of Medicine, Division of Medical Oncology, Istanbul University, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Toi, Masakazu" sort="Toi, Masakazu" uniqKey="Toi M" first="Masakazu" last="Toi">Masakazu Toi</name><affiliation wicri:level="4"><nlm:affiliation>Kyoto University, Sakyo-ku, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Kyoto University, Sakyo-ku, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Xu, Binghe" sort="Xu, Binghe" uniqKey="Xu B" first="Binghe" last="Xu">Binghe Xu</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Jerusalem, Guy" sort="Jerusalem, Guy" uniqKey="Jerusalem G" first="Guy" last="Jerusalem">Guy Jerusalem</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Universitaire du Sart-Tilman, Domaine Universitaire B35, Liège, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Centre Hospitalier Universitaire du Sart-Tilman, Domaine Universitaire B35, Liège</wicri:regionArea><wicri:noRegion>Liège</wicri:noRegion></affiliation></author><author><name sortKey="Masuda, Norikazu" sort="Masuda, Norikazu" uniqKey="Masuda N" first="Norikazu" last="Masuda">Norikazu Masuda</name><affiliation wicri:level="1"><nlm:affiliation>NHO Osaka National Hospital, Chuou-ku, Osaka, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>NHO Osaka National Hospital, Chuou-ku, Osaka</wicri:regionArea><wicri:noRegion>Osaka</wicri:noRegion></affiliation></author><author><name sortKey="Wilks, Sharon" sort="Wilks, Sharon" uniqKey="Wilks S" first="Sharon" last="Wilks">Sharon Wilks</name><affiliation wicri:level="2"><nlm:affiliation>Cancer Care Centers of South Texas, San Antonio, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cancer Care Centers of South Texas, San Antonio, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Arena, Francis" sort="Arena, Francis" uniqKey="Arena F" first="Francis" last="Arena">Francis Arena</name><affiliation wicri:level="2"><nlm:affiliation>NYU Langone Arena Oncology, Lake Success, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>NYU Langone Arena Oncology, Lake Success, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Isaacs, Claudine" sort="Isaacs, Claudine" uniqKey="Isaacs C" first="Claudine" last="Isaacs">Claudine Isaacs</name><affiliation wicri:level="2"><nlm:affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Yap, Yoon Sim" sort="Yap, Yoon Sim" uniqKey="Yap Y" first="Yoon-Sim" last="Yap">Yoon-Sim Yap</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Centre Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>National Cancer Centre Singapore</wicri:regionArea></affiliation></author><author><name sortKey="Papai, Zsuzsanna" sort="Papai, Zsuzsanna" uniqKey="Papai Z" first="Zsuzsanna" last="Papai">Zsuzsanna Papai</name><affiliation wicri:level="3"><nlm:affiliation>Oncology Department, Military Hospital, Budapest, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Oncology Department, Military Hospital, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Lang, Istvan" sort="Lang, Istvan" uniqKey="Lang I" first="Istvan" last="Lang">Istvan Lang</name><affiliation wicri:level="3"><nlm:affiliation>Orszagos Onkologiai Intezet, Budapest, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Orszagos Onkologiai Intezet, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Armstrong, Anne" sort="Armstrong, Anne" uniqKey="Armstrong A" first="Anne" last="Armstrong">Anne Armstrong</name><affiliation wicri:level="3"><nlm:affiliation>Christie Hospital NHS Foundation Trust, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Christie Hospital NHS Foundation Trust, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Lerzo, Guillermo" sort="Lerzo, Guillermo" uniqKey="Lerzo G" first="Guillermo" last="Lerzo">Guillermo Lerzo</name><affiliation wicri:level="1"><nlm:affiliation>Sanatorio de la Providencia, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Sanatorio de la Providencia, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="White, Michelle" sort="White, Michelle" uniqKey="White M" first="Michelle" last="White">Michelle White</name><affiliation wicri:level="1"><nlm:affiliation>Monash Medical Center, Moorabbin Hospital, Bentleigh East, VIC, Australia; Cabrini Brighton Hospital, Brighton, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash Medical Center, Moorabbin Hospital, Bentleigh East, VIC, Australia; Cabrini Brighton Hospital, Brighton, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Shen, Kunwei" sort="Shen, Kunwei" uniqKey="Shen K" first="Kunwei" last="Shen">Kunwei Shen</name><affiliation wicri:level="1"><nlm:affiliation>Comprehensive Breast Health Center, RuiJin Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Comprehensive Breast Health Center, RuiJin Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Litton, Jennifer" sort="Litton, Jennifer" uniqKey="Litton J" first="Jennifer" last="Litton">Jennifer Litton</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Chen, David" sort="Chen, David" uniqKey="Chen D" first="David" last="Chen">David Chen</name><affiliation wicri:level="2"><nlm:affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Zhang, Yufen" sort="Zhang, Yufen" uniqKey="Zhang Y" first="Yufen" last="Zhang">Yufen Zhang</name><affiliation wicri:level="2"><nlm:affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ali, Shyanne" sort="Ali, Shyanne" uniqKey="Ali S" first="Shyanne" last="Ali">Shyanne Ali</name><affiliation wicri:level="2"><nlm:affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Taran, Tetiana" sort="Taran, Tetiana" uniqKey="Taran T" first="Tetiana" last="Taran">Tetiana Taran</name><affiliation wicri:level="2"><nlm:affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Gianni, Luca" sort="Gianni, Luca" uniqKey="Gianni L" first="Luca" last="Gianni">Luca Gianni</name><affiliation wicri:level="3"><nlm:affiliation>Ospedale San Raffaele Scientific Institute, Milan, Italy. Electronic address: gianni.luca@hsr.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale San Raffaele Scientific Institute, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24742739</idno><idno type="pmid">24742739</idno><idno type="doi">10.1016/S1470-2045(14)70138-X</idno><idno type="wicri:Area/PubMed/Corpus">003810</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003810</idno><idno type="wicri:Area/PubMed/Curation">003696</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003696</idno><idno type="wicri:Area/PubMed/Checkpoint">003696</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003696</idno><idno type="wicri:Area/Ncbi/Merge">001967</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.</title><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, INSERM Unit U981, Université Paris Sud, Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, INSERM Unit U981, Université Paris Sud, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="O Regan, Ruth" sort="O Regan, Ruth" uniqKey="O Regan R" first="Ruth" last="O'Regan">Ruth O'Regan</name><affiliation wicri:level="2"><nlm:affiliation>Winship Cancer Institute of Emory University, Atlanta, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Winship Cancer Institute of Emory University, Atlanta, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Ozguroglu, Mustafa" sort="Ozguroglu, Mustafa" uniqKey="Ozguroglu M" first="Mustafa" last="Ozguroglu">Mustafa Ozguroglu</name><affiliation wicri:level="1"><nlm:affiliation>Cerrahpasa Medical Faculty, Department of Medicine, Division of Medical Oncology, Istanbul University, Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Cerrahpasa Medical Faculty, Department of Medicine, Division of Medical Oncology, Istanbul University, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Toi, Masakazu" sort="Toi, Masakazu" uniqKey="Toi M" first="Masakazu" last="Toi">Masakazu Toi</name><affiliation wicri:level="4"><nlm:affiliation>Kyoto University, Sakyo-ku, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Kyoto University, Sakyo-ku, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Xu, Binghe" sort="Xu, Binghe" uniqKey="Xu B" first="Binghe" last="Xu">Binghe Xu</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Jerusalem, Guy" sort="Jerusalem, Guy" uniqKey="Jerusalem G" first="Guy" last="Jerusalem">Guy Jerusalem</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Universitaire du Sart-Tilman, Domaine Universitaire B35, Liège, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Centre Hospitalier Universitaire du Sart-Tilman, Domaine Universitaire B35, Liège</wicri:regionArea><wicri:noRegion>Liège</wicri:noRegion></affiliation></author><author><name sortKey="Masuda, Norikazu" sort="Masuda, Norikazu" uniqKey="Masuda N" first="Norikazu" last="Masuda">Norikazu Masuda</name><affiliation wicri:level="1"><nlm:affiliation>NHO Osaka National Hospital, Chuou-ku, Osaka, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>NHO Osaka National Hospital, Chuou-ku, Osaka</wicri:regionArea><wicri:noRegion>Osaka</wicri:noRegion></affiliation></author><author><name sortKey="Wilks, Sharon" sort="Wilks, Sharon" uniqKey="Wilks S" first="Sharon" last="Wilks">Sharon Wilks</name><affiliation wicri:level="2"><nlm:affiliation>Cancer Care Centers of South Texas, San Antonio, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cancer Care Centers of South Texas, San Antonio, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Arena, Francis" sort="Arena, Francis" uniqKey="Arena F" first="Francis" last="Arena">Francis Arena</name><affiliation wicri:level="2"><nlm:affiliation>NYU Langone Arena Oncology, Lake Success, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>NYU Langone Arena Oncology, Lake Success, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Isaacs, Claudine" sort="Isaacs, Claudine" uniqKey="Isaacs C" first="Claudine" last="Isaacs">Claudine Isaacs</name><affiliation wicri:level="2"><nlm:affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Yap, Yoon Sim" sort="Yap, Yoon Sim" uniqKey="Yap Y" first="Yoon-Sim" last="Yap">Yoon-Sim Yap</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Centre Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>National Cancer Centre Singapore</wicri:regionArea></affiliation></author><author><name sortKey="Papai, Zsuzsanna" sort="Papai, Zsuzsanna" uniqKey="Papai Z" first="Zsuzsanna" last="Papai">Zsuzsanna Papai</name><affiliation wicri:level="3"><nlm:affiliation>Oncology Department, Military Hospital, Budapest, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Oncology Department, Military Hospital, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Lang, Istvan" sort="Lang, Istvan" uniqKey="Lang I" first="Istvan" last="Lang">Istvan Lang</name><affiliation wicri:level="3"><nlm:affiliation>Orszagos Onkologiai Intezet, Budapest, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Orszagos Onkologiai Intezet, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Armstrong, Anne" sort="Armstrong, Anne" uniqKey="Armstrong A" first="Anne" last="Armstrong">Anne Armstrong</name><affiliation wicri:level="3"><nlm:affiliation>Christie Hospital NHS Foundation Trust, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Christie Hospital NHS Foundation Trust, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Lerzo, Guillermo" sort="Lerzo, Guillermo" uniqKey="Lerzo G" first="Guillermo" last="Lerzo">Guillermo Lerzo</name><affiliation wicri:level="1"><nlm:affiliation>Sanatorio de la Providencia, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Sanatorio de la Providencia, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="White, Michelle" sort="White, Michelle" uniqKey="White M" first="Michelle" last="White">Michelle White</name><affiliation wicri:level="1"><nlm:affiliation>Monash Medical Center, Moorabbin Hospital, Bentleigh East, VIC, Australia; Cabrini Brighton Hospital, Brighton, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash Medical Center, Moorabbin Hospital, Bentleigh East, VIC, Australia; Cabrini Brighton Hospital, Brighton, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Shen, Kunwei" sort="Shen, Kunwei" uniqKey="Shen K" first="Kunwei" last="Shen">Kunwei Shen</name><affiliation wicri:level="1"><nlm:affiliation>Comprehensive Breast Health Center, RuiJin Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Comprehensive Breast Health Center, RuiJin Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Litton, Jennifer" sort="Litton, Jennifer" uniqKey="Litton J" first="Jennifer" last="Litton">Jennifer Litton</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Chen, David" sort="Chen, David" uniqKey="Chen D" first="David" last="Chen">David Chen</name><affiliation wicri:level="2"><nlm:affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Zhang, Yufen" sort="Zhang, Yufen" uniqKey="Zhang Y" first="Yufen" last="Zhang">Yufen Zhang</name><affiliation wicri:level="2"><nlm:affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ali, Shyanne" sort="Ali, Shyanne" uniqKey="Ali S" first="Shyanne" last="Ali">Shyanne Ali</name><affiliation wicri:level="2"><nlm:affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Taran, Tetiana" sort="Taran, Tetiana" uniqKey="Taran T" first="Tetiana" last="Taran">Tetiana Taran</name><affiliation wicri:level="2"><nlm:affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Gianni, Luca" sort="Gianni, Luca" uniqKey="Gianni L" first="Luca" last="Gianni">Luca Gianni</name><affiliation wicri:level="3"><nlm:affiliation>Ospedale San Raffaele Scientific Institute, Milan, Italy. Electronic address: gianni.luca@hsr.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale San Raffaele Scientific Institute, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (genetics)</term><term>Breast Neoplasms (mortality)</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Drug Resistance, Neoplasm (drug effects)</term><term>Everolimus</term><term>Female</term><term>Genes, erbB-2</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Sirolimus (analogs & derivatives)</term><term>Sirolimus (therapeutic use)</term><term>Trastuzumab</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Gènes erbB-2</term><term>Humains</term><term>Modèles de hasards proportionnels</term><term>Méthode en double aveugle</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Résistance aux médicaments antinéoplasiques ()</term><term>Résultat thérapeutique</term><term>Sirolimus (analogues et dérivés)</term><term>Sirolimus (usage thérapeutique)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Trastuzumab</term><term>Tumeurs du sein (génétique)</term><term>Tumeurs du sein (mortalité)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Évérolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Neoplasm</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Sirolimus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Everolimus</term><term>Female</term><term>Genes, erbB-2</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Trastuzumab</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Gènes erbB-2</term><term>Humains</term><term>Modèles de hasards proportionnels</term><term>Méthode en double aveugle</term><term>Résistance aux médicaments antinéoplasiques</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Trastuzumab</term><term>Évérolimus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24742739</PMID><DateCreated><Year>2014</Year><Month>05</Month><Day>08</Day></DateCreated><DateCompleted><Year>2014</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol.</ISOAbbreviation></Journal><ArticleTitle>Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.</ArticleTitle><Pagination><MedlinePgn>580-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(14)70138-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(14)70138-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited women with HER2-positive, trastuzumab-resistant, advanced breast carcinoma who had previously received taxane therapy. Eligible patients were randomly assigned (1:1) using a central patient screening and randomisation system to daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m(2)) or to placebo plus trastuzumab plus vinorelbine, in 3-week cycles, stratified by previous lapatinib use. The primary endpoint was progression-free survival (PFS) by local assessment in the intention-to-treat population. We report the final analysis for PFS; overall survival follow-up is still in progress. This trial is registered with ClinicalTrials.gov, number NCT01007942.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between Oct 26, 2009, and May 23, 2012, 569 patients were randomly assigned to everolimus (n=284) or placebo (n=285). Median follow-up at the time of analysis was 20.2 months (IQR 15.0-27.1). Median PFS was 7.00 months (95% CI 6.74-8.18) with everolimus and 5.78 months (5.49-6.90) with placebo (hazard ratio 0.78 [95% CI 0.65-0.95]; p=0.0067). The most common grade 3-4 adverse events were neutropenia (204 [73%] of 280 patients in the everolimus group vs 175 [62%] of 282 patients in the placebo group), leucopenia (106 [38%] vs 82 [29%]), anaemia (53 [19%] vs 17 [6%]), febrile neutropenia (44 [16%] vs ten [4%]), stomatitis (37 [13%] vs four [1%]), and fatigue (34 [12%] vs 11 [4%]). Serious adverse events were reported in 117 (42%) patients in the everolimus group and 55 (20%) in the placebo group; two on-treatment deaths due to adverse events occurred in each group.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The addition of everolimus to trastuzumab plus vinorelbine significantly prolongs PFS in patients with trastuzumab-resistant and taxane-pretreated, HER2-positive, advanced breast cancer. The clinical benefit should be considered in the context of the adverse event profile in this population.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>André</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, INSERM Unit U981, Université Paris Sud, Institut Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Regan</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Winship Cancer Institute of Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozguroglu</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cerrahpasa Medical Faculty, Department of Medicine, Division of Medical Oncology, Istanbul University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toi</LastName><ForeName>Masakazu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Kyoto University, Sakyo-ku, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Binghe</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jerusalem</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire du Sart-Tilman, Domaine Universitaire B35, Liège, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masuda</LastName><ForeName>Norikazu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>NHO Osaka National Hospital, Chuou-ku, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilks</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cancer Care Centers of South Texas, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arena</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NYU Langone Arena Oncology, Lake Success, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Claudine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yap</LastName><ForeName>Yoon-Sim</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>National Cancer Centre Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papai</LastName><ForeName>Zsuzsanna</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Oncology Department, Military Hospital, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Istvan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Orszagos Onkologiai Intezet, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Christie Hospital NHS Foundation Trust, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerzo</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sanatorio de la Providencia, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Monash Medical Center, Moorabbin Hospital, Bentleigh East, VIC, Australia; Cabrini Brighton Hospital, Brighton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Kunwei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Comprehensive Breast Health Center, RuiJin Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litton</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yufen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Shyanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taran</LastName><ForeName>Tetiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianni</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ospedale San Raffaele Scientific Institute, Milan, Italy. Electronic address: gianni.luca@hsr.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01007942</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>9HW64Q8G6G</RegistryNumber><NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2014 Jul;15(8):e304-5</RefSource><PMID Version="1">24988930</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2014 May;15(6):541-2</RefSource><PMID Version="1">24807856</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2014 Jul;15(8):e304</RefSource><PMID Version="1">24988929</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018734" MajorTopicYN="N">Genes, erbB-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24742739</ArticleId><ArticleId IdType="pii">S1470-2045(14)70138-X</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(14)70138-X</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Argentine</li><li>Australie</li><li>Belgique</li><li>France</li><li>Hongrie</li><li>Italie</li><li>Japon</li><li>Royaume-Uni</li><li>République populaire de Chine</li><li>Singapour</li><li>Turquie</li><li>États-Unis</li></country><region><li>Angleterre</li><li>District de Columbia</li><li>Grand Manchester</li><li>Géorgie (États-Unis)</li><li>Hongrie centrale</li><li>Lombardie</li><li>New Jersey</li><li>Région du Kansai</li><li>Texas</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Budapest</li><li>Kyoto</li><li>Manchester</li><li>Milan</li><li>Orsay</li><li>Pékin</li></settlement><orgName><li>Université Paris-Sud</li><li>Université de Kyoto</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name></region></country><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="O Regan, Ruth" sort="O Regan, Ruth" uniqKey="O Regan R" first="Ruth" last="O'Regan">Ruth O'Regan</name></region><name sortKey="Ali, Shyanne" sort="Ali, Shyanne" uniqKey="Ali S" first="Shyanne" last="Ali">Shyanne Ali</name><name sortKey="Arena, Francis" sort="Arena, Francis" uniqKey="Arena F" first="Francis" last="Arena">Francis Arena</name><name sortKey="Chen, David" sort="Chen, David" uniqKey="Chen D" first="David" last="Chen">David Chen</name><name sortKey="Isaacs, Claudine" sort="Isaacs, Claudine" uniqKey="Isaacs C" first="Claudine" last="Isaacs">Claudine Isaacs</name><name sortKey="Litton, Jennifer" sort="Litton, Jennifer" uniqKey="Litton J" first="Jennifer" last="Litton">Jennifer Litton</name><name sortKey="Taran, Tetiana" sort="Taran, Tetiana" uniqKey="Taran T" first="Tetiana" last="Taran">Tetiana Taran</name><name sortKey="Wilks, Sharon" sort="Wilks, Sharon" uniqKey="Wilks S" first="Sharon" last="Wilks">Sharon Wilks</name><name sortKey="Zhang, Yufen" sort="Zhang, Yufen" uniqKey="Zhang Y" first="Yufen" last="Zhang">Yufen Zhang</name></country><country name="Turquie"><noRegion><name sortKey="Ozguroglu, Mustafa" sort="Ozguroglu, Mustafa" uniqKey="Ozguroglu M" first="Mustafa" last="Ozguroglu">Mustafa Ozguroglu</name></noRegion></country><country name="Japon"><region name="Région du Kansai"><name sortKey="Toi, Masakazu" sort="Toi, Masakazu" uniqKey="Toi M" first="Masakazu" last="Toi">Masakazu Toi</name></region><name sortKey="Masuda, Norikazu" sort="Masuda, Norikazu" uniqKey="Masuda N" first="Norikazu" last="Masuda">Norikazu Masuda</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Xu, Binghe" sort="Xu, Binghe" uniqKey="Xu B" first="Binghe" last="Xu">Binghe Xu</name></noRegion><name sortKey="Shen, Kunwei" sort="Shen, Kunwei" uniqKey="Shen K" first="Kunwei" last="Shen">Kunwei Shen</name></country><country name="Belgique"><noRegion><name sortKey="Jerusalem, Guy" sort="Jerusalem, Guy" uniqKey="Jerusalem G" first="Guy" last="Jerusalem">Guy Jerusalem</name></noRegion></country><country name="Singapour"><noRegion><name sortKey="Yap, Yoon Sim" sort="Yap, Yoon Sim" uniqKey="Yap Y" first="Yoon-Sim" last="Yap">Yoon-Sim Yap</name></noRegion></country><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Papai, Zsuzsanna" sort="Papai, Zsuzsanna" uniqKey="Papai Z" first="Zsuzsanna" last="Papai">Zsuzsanna Papai</name></region><name sortKey="Lang, Istvan" sort="Lang, Istvan" uniqKey="Lang I" first="Istvan" last="Lang">Istvan Lang</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Armstrong, Anne" sort="Armstrong, Anne" uniqKey="Armstrong A" first="Anne" last="Armstrong">Anne Armstrong</name></region></country><country name="Argentine"><noRegion><name sortKey="Lerzo, Guillermo" sort="Lerzo, Guillermo" uniqKey="Lerzo G" first="Guillermo" last="Lerzo">Guillermo Lerzo</name></noRegion></country><country name="Australie"><noRegion><name sortKey="White, Michelle" sort="White, Michelle" uniqKey="White M" first="Michelle" last="White">Michelle White</name></noRegion></country><country name="Italie"><region name="Lombardie"><name sortKey="Gianni, Luca" sort="Gianni, Luca" uniqKey="Gianni L" first="Luca" last="Gianni">Luca Gianni</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001967 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001967 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:24742739
|texte= Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:24742739" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |